United Therapeutics Corporation

UTHR · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

$498.48-1.87 (-0.37%)

Close Sep 16, 2026 · end-of-day

Market Stats

Previous Close$500.35

Open$500.62

Day Range$497.67 – $505.78

52-Week Range$409.07 – $609.35

Volume464.25K

Market Cap$20.83B

P/E (TTM)17.40

Forward P/E16.42

EPS$27.91

Dividend Yield0.00%

Beta0.56

50-Day Avg$511.82

200-Day Avg$524.45

Price History

Open in new tab

Loading price history…

About

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Company Details

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Employees: 1.40K
Headquarters: 1000 Spring Street, Silver Spring, MD, United States, 20910, USA
Website: https://www.unither.com

Leadership

Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.Founder, Chairman & CEO · b. 1955
Mr. Michael I. BenkowitzPresident & COO · b. 1972
Mr. James C. EdgemondCFO & Treasurer · b. 1968
Mr. Paul A. Mahon J.D.Executive VP, General Counsel & Corporate Secretary · b. 1964
Harrison SilversManager of Investor Relations
Ms. Holly HobsonAssociate Vice President of Human Resources
Mr. Patrick PoissonExecutive Vice President of Strategic Development · b. 1968
Dr. Leigh PetersonExecutive Vice President of Product Development & Xenotransplantation
Mr. Gil GoldenSenior VP & Chief Medical Officer

Financials

Income Statement

Line item	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Total Revenue	$3.18B	$2.88B	$2.33B	$1.94B	$1.69B	$1.48B	$1.45B	$1.63B	$1.73B	$1.60B	$1.47B	$1.29B	$1.12B	$916.08M	$743.18M	$603.83M	$369.85M	$281.50M	$210.94M	$159.63M	$115.92M	$73.59M	$53.34M	$30.12M	$5.73M	$2.05M	$400.00K	$100.00K
Cost of Revenue	$384.40M	$309.70M	$257.50M	$146.70M	$122.50M	$108.10M	$117.60M	$198.70M	$105.70M	$72.70M	$69.04M	$125.88M	$131.13M	$119.30M	$88.90M	$73.47M	$45.32M	$30.07M	$22.26M	$17.03M	$12.31M	$8.25M	$6.78M	$5.46M	$3.14M	$1.71M	$1.40M	-
Gross Profit	$2.80B	$2.57B	$2.07B	$1.79B	$1.56B	$1.38B	$1.33B	$1.43B	$1.62B	$1.53B	$1.40B	$1.16B	$985.86M	$796.78M	$654.28M	$530.37M	$324.53M	$251.43M	$188.68M	$142.60M	$103.60M	$65.34M	$46.56M	$24.66M	$2.59M	$343.47K	$-1.00M	$100.00K
Operating Income	$1.52B	$1.38B	$1.18B	$979.70M	$555.90M	$593.60M	$-187.60M	$805.40M	$814.90M	$1.06B	$699.01M	$538.80M	$292.50M	$421.65M	$317.78M	$164.00M	$26.00M	$-82.06M	$6.30M	$28.98M	$42.89M	$13.21M	$-11.53M	$-18.00M	$-46.94M	$-81.50M	$-35.40M	$-13.30M
EBITDA	$1.82B	$1.65B	$1.39B	$1.04B	$736.80M	$646.30M	$-74.90M	$838.40M	$1.05B	$1.09B	$1.08B	$575.02M	$323.76M	$484.45M	$341.02M	$185.47M	$43.04M	$-67.75M	$22.18M	$28.98M	$50.09M	$17.83M	$-9.20M	$-14.87M	$-43.23M	$-81.58M	$-36.66M	$-13.35M
Net Income	$1.33B	$1.20B	$984.80M	$727.30M	$475.80M	$514.80M	$-104.50M	$589.20M	$417.90M	$713.70M	$651.64M	$340.07M	$174.56M	$304.44M	$217.87M	$105.92M	$19.46M	$-42.79M	$19.86M	$73.97M	$65.02M	$15.45M	$-9.97M	$-23.65M	$-37.29M	$-75.61M	$-33.50M	$-12.80M
R&D	$550.00M	$481.00M	$408.00M	$322.90M	$540.10M	$357.70M	$1.18B	$357.90M	$264.60M	$147.60M	$245.10M	$242.55M	$299.35M	$173.39M	$180.01M	$166.76M	$122.19M	$239.18M	$83.35M	$57.57M	$36.05M	$30.60M	$35.42M	$26.78M	$32.59M	$70.19M	$30.70M	$11.00M
Interest Expense	$19.50M	$42.90M	$59.30M	$32.40M	$18.60M	$23.50M	$44.20M	$13.90M	$9.00M	$3.90M	$4.74M	$17.59M	$18.06M	$16.64M	$21.37M	$19.71M	$12.88M	$16.00K	$2.17M	$482.00K	$29.00K	$4.00K	$112.00K	$117.00K	$172.72K	$120.03K	$0	-

Balance Sheet

Line item	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Total Assets	$7.88B	$7.36B	$7.17B	$6.04B	$5.17B	$4.62B	$3.91B	$3.40B	$2.88B	$2.33B	$2.18B	$1.88B	$2.09B	$1.63B	$1.52B	$1.43B	$1.05B	$871.32M	$587.02M	$478.55M	$291.41M	$207.16M	$179.50M	$184.57M	$212.12M	$250.64M	$59.90M	$18.70M
Total Liabilities	$783.80M	$920.00M	$1.18B	$1.25B	$1.21B	$1.22B	$1.13B	$612.40M	$777.60M	$463.40M	$584.80M	$618.84M	$783.26M	$531.73M	$569.59M	$547.75M	$398.54M	$363.62M	$291.23M	$273.94M	$16.31M	$15.52M	$11.74M	$12.91M	$15.72M	$15.91M	$6.30M	$2.00M
Total Equity	$7.10B	$6.44B	$5.98B	$4.80B	$3.96B	$3.40B	$2.78B	$2.79B	$2.10B	$1.86B	$1.60B	$1.27B	$1.30B	$1.09B	$948.49M	$883.89M	$653.01M	$507.70M	$295.79M	$204.61M	$275.10M	$191.64M	$167.76M	$171.66M	$196.40M	$234.74M	$53.60M	$16.70M
Cash	$1.56B	$1.70B	$1.21B	$961.20M	$894.80M	$738.70M	$738.40M	$669.20M	$705.10M	$1.02B	$831.80M	$397.70M	$278.89M	$154.03M	$162.68M	$252.16M	$100.35M	$129.45M	$139.32M	$91.07M	$69.18M	$82.59M	$68.56M	$122.66M	$24.37M	$200.94M	$18.30M	$6.80M
Total Debt	$37.60M	$300.00M	$700.00M	$800.00M	$800.00M	$800.00M	$850.00M	$250.00M	$250.00M	-	$5.39M	$126.41M	$286.18M	$276.30M	$265.63M	$304.90M	$250.60M	$234.95M	$250.00M	$250.03M	$23.00K	$26.00K	$798.00K	$1.88M	$1.94M	$1.91M	$1.90M	$300.00K
Net Debt	$-1.52B	$-1.40B	$-507.70M	$-161.20M	$-94.80M	$61.30M	$111.60M	$-419.20M	$-455.10M	$-1.02B	$-826.41M	$-271.28M	$1.93M	$122.27M	$102.96M	$52.73M	$150.25M	$105.50M	$110.68M	$158.96M	$-69.16M	$-82.56M	$-67.76M	$-120.78M	$-22.43M	$-199.03M	$-16.40M	$-6.50M

Cash Flow

Line item	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Operating Cash Flow	$1.56B	$1.33B	$978.00M	$802.50M	$598.20M	$755.70M	$-206.60M	$778.40M	$474.20M	$643.60M	$382.80M	$355.30M	$425.27M	$323.63M	$250.19M	$211.53M	$99.72M	$-49.20M	$48.95M	$49.39M	$43.17M	$20.78M	$-8.56M	$-22.26M	$-38.90M	$-31.11M	$-23.70M	$-9.60M
Investing Cash Flow	$-551.30M	$417.20M	$-719.60M	$-811.50M	$-486.90M	$-738.50M	$-335.40M	$-820.60M	$-835.60M	$48.30M	$503.60M	$338.50M	$-294.97M	$-163.36M	$-121.33M	$-209.24M	$-160.52M	$-172.48M	$-21.71M	$-104.03M	$-71.28M	$-12.87M	$-47.54M	$120.36M	-	$7.16M	$-24.10M	$-11.50M
Financing Cash Flow	$-1.15B	$-1.25B	$-11.90M	$75.40M	$44.80M	$-16.90M	$611.20M	$6.30M	$43.30M	$-497.70M	$-447.00M	$-576.60M	$-5.12M	$-169.14M	$-218.08M	$146.76M	$36.48M	$213.00M	$20.88M	$74.13M	$14.17M	$6.32M	$2.01M	$185.00K	$-2.88M	$206.61M	$59.30M	$22.90M
Capital Expenditure	$520.50M	$246.50M	$230.40M	$138.80M	$120.80M	$59.30M	$83.70M	$184.40M	$86.30M	$43.20M	$49.79M	$47.44M	$31.91M	$111.91M	$35.98M	$18.64M	$95.40M	$124.42M	$38.66M	$15.63M	$6.12M	$5.22M	$7.00M	$3.58M	$687.29K	$639.88K	$2.30M	$1.00M
Free Cash Flow	$1.04B	$1.08B	$747.60M	$663.70M	$477.40M	$696.40M	$-290.30M	$594.00M	$387.90M	$600.40M	$333.01M	$307.86M	$393.36M	$211.72M	$214.22M	$192.89M	$2.22M	$-173.59M	$10.43M	$36.15M	$37.58M	$15.56M	$-15.57M	$-25.84M	$-39.59M	$-31.75M	$-26.00M	$-10.60M
Dividends Paid	-	-	$98.00M	$94.30M	-	$38.50M	$14.00M	-	$0	$7.70M	$39.31M	$190.17M	$26.61M	$0	$0	$0	-	-	$29.60M	-	-	-	-	-	-	-	-	-

Earnings

Report Date	Nov 4, 2026	Aug 5, 2026	May 6, 2026	Feb 25, 2026	Oct 29, 2025	Jul 30, 2025	Apr 30, 2025	Feb 19, 2025	Oct 30, 2024	Jul 31, 2024	May 1, 2024	Feb 21, 2024	Nov 1, 2023	Aug 2, 2023	May 3, 2023	Feb 22, 2023	Nov 2, 2022	Aug 3, 2022	May 4, 2022	Feb 24, 2022	Nov 3, 2021	Aug 4, 2021	May 5, 2021	Feb 24, 2021	Oct 28, 2020	Jul 29, 2020	Apr 29, 2020	Feb 26, 2020	Oct 30, 2019	Jul 31, 2019	May 1, 2019	Feb 27, 2019	Oct 31, 2018	Aug 1, 2018	May 2, 2018	Feb 21, 2018	Oct 25, 2017	Jul 27, 2017	Apr 26, 2017	Feb 22, 2017	Oct 27, 2016	Jul 28, 2016	Apr 28, 2016	Feb 25, 2016	Oct 27, 2015	Jul 28, 2015	Apr 28, 2015	Feb 24, 2015	Oct 28, 2014	Jul 29, 2014	Apr 29, 2014	Feb 25, 2014	Oct 29, 2013	Jul 25, 2013	Apr 25, 2013	Feb 26, 2013	Nov 1, 2012	Jul 26, 2012	Apr 26, 2012	Feb 14, 2012	Oct 27, 2011	Jul 28, 2011	Apr 28, 2011	Feb 15, 2011	Oct 28, 2010	Jul 28, 2010	Apr 29, 2010	Feb 16, 2010	Oct 29, 2009	Jul 31, 2009	May 1, 2009	Feb 17, 2009	Oct 30, 2008	Jul 31, 2008	May 1, 2008	Feb 19, 2008	Nov 1, 2007	Jul 31, 2007	May 1, 2007	Feb 20, 2007	Oct 31, 2006	Aug 1, 2006	May 2, 2006	Feb 21, 2006	Oct 31, 2005	Aug 2, 2005	May 3, 2005	Feb 22, 2005	Nov 3, 2004	Aug 3, 2004	May 6, 2004	Feb 24, 2004	Nov 6, 2003	Aug 5, 2003	May 6, 2003	Feb 25, 2003	Nov 8, 2002	Jun 30, 2002	Mar 31, 2002	Dec 31, 2001	Sep 30, 2001	Aug 10, 2001	May 9, 2001	Mar 21, 2001	Nov 1, 2000	Aug 8, 2000	May 9, 2000	Mar 2, 2000	Nov 8, 1999	Jun 30, 1999
EPS Estimate	$6.38	$6.82	$6.86	$7.10	$6.96	$7.30	$6.54	$6.27	$7.12	$6.41	$5.59	$4.19	$5.04	$4.78	$4.71	$4.51	$3.77	$4.54	$3.07	$3.72	$3.58	$3.56	$3.49	$3.14	$3.34	$3.28	$3.39	$2.68	$2.90	$2.74	$2.77	$2.55	$3.03	$3.42	$4.00	$3.89	$4.80	$3.66	$3.82	$3.61	$3.79	$3.16	$3.16	$2.55	$3.39	$2.31	$2.13	$2.03	$1.93	$1.70	$1.54	$1.51	$1.64	$1.51	$1.47	$1.25	$1.26	$1.13	$0.93	$0.87	$0.73	$0.53	$0.92	$0.62	$0.63	$0.63	$0.29	$0.31	$0.31	$0.29	$0.31	$0.26	$0.29	$0.28	$0.27	$0.22	$0.16	$0.15	$0.14	$0.35	$0.14	$0.10	$0.25	$0.33	$0.24	$0.17	$0.14	$0.10	$0.08	$0.01	$-0.01	$-0.04	$-0.03	$-0.05	$-0.09	$-0.08	$-0.29	-	-	-	-	$-0.24	$-0.23	$-0.22	$-0.33	$-0.28	$-0.24	$-0.28	$-0.26	-
EPS Actual	-	$7.27	$5.82	$7.70	$7.16	$6.41	$6.63	$6.19	$7.07	$5.85	$6.17	$4.36	$5.38	$5.24	$4.86	$2.67	$4.91	$3.46	$5.03	$2.35	$3.42	$4.09	$3.49	$2.19	$3.88	$3.68	$3.61	$1.20	$3.83	$3.63	$-11.32	$1.48	$2.42	$4.36	$3.76	$3.89	$4.69	$4.37	$3.61	$2.49	$4.36	$4.39	$3.02	$2.10	$9.24	$1.91	$-0.36	$2.37	$-0.53	$2.10	$2.43	$-0.60	$1.17	$1.52	$1.19	$1.60	$1.46	$1.34	$1.29	$0.77	$1.38	$1.18	$0.32	$0.15	$0.66	$0.62	$0.32	$-0.06	$0.21	$-0.04	$0.28	$-1.71	$0.25	$0.30	$0.24	$0.04	$0.33	$0.13	$-0.06	$0.38	$0.17	$0.15	$0.20	$0.57	$0.31	$0.25	$0.16	$0.14	$0.14	$0.09	$-0.04	$-0.07	$-0.03	$-0.05	$-0.07	$-0.06	$-0.29	$-0.08	$-0.14	$-0.18	$-0.24	$-0.26	$-0.23	$-0.29	$-0.17	$-0.24	$-0.22	$-0.28	$-0.20	$-0.27
Surprise	-	6.60%	-15.16%	8.45%	2.87%	-12.19%	1.38%	-1.23%	-0.70%	-8.74%	10.38%	4.06%	6.75%	9.62%	3.18%	-40.80%	30.24%	-23.79%	63.84%	-36.83%	-4.47%	14.89%	0.00%	-30.25%	16.17%	12.20%	6.49%	-55.22%	32.07%	32.48%	-508.66%	-41.96%	-20.13%	27.49%	-6.00%	0.00%	-2.29%	19.40%	-5.50%	-31.02%	15.04%	38.92%	-4.43%	-17.65%	172.57%	-17.32%	-116.90%	16.75%	-127.46%	23.53%	57.79%	-139.74%	-28.66%	0.66%	-19.05%	28.00%	15.87%	18.58%	38.71%	-11.49%	89.04%	122.64%	-65.22%	-75.81%	4.76%	-1.59%	10.34%	-119.35%	-32.26%	-113.79%	-9.68%	-757.69%	-13.79%	7.14%	-11.11%	-81.82%	106.25%	-13.33%	-142.86%	8.57%	21.43%	50.00%	-20.00%	72.73%	29.17%	47.06%	14.29%	40.00%	75.00%	800.00%	-300.00%	-75.00%	0.00%	0.00%	22.22%	25.00%	0.00%	-	-	-	-	-8.33%	0.00%	-31.82%	48.48%	14.29%	8.33%	0.00%	23.08%	-
Timing	-	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	-	Pre-market	Pre-market	Pre-market	-	Pre-market	-	-	-	-	-	-	Pre-market	After-hours	After-hours	Pre-market	-	-	-

Key Statistics & Ratios

Market Cap: $20.83B
Enterprise Value: $18.22B
Trailing P/E: 17.40
Forward P/E: 16.42
PEG Ratio: 2.22
Price / Sales: 6.60
Price / Book: 3.33
EPS: $27.91
Book Value: $149.97
Revenue (TTM): $3.15B
Gross Profit (TTM): $2.72B
EBITDA: $1.50B
Profit Margin: 41.56%
Operating Margin: 42.23%
Return on Equity: 19.32%
Return on Assets: 11.61%
Shares Outstanding: 42.89M
Shares Float: 39.21M
Beta: 0.56
Dividend Yield: 0.00%
Dividend Rate: $0
Payout Ratio: 0.00%

Analyst Ratings

Sell

Based on 15 analystsTarget $637.92

Strong Buy
9
Buy
3
Hold
3

Ownership Breakdown

Institutions: 99.87%
Insiders: 2.00%
Retail / Other: 0.00%

Top Institutional Holders

BlackRock Inc
5.40M12.37%
venBio Select Advisor LLC
2.63M6.03%
Vanguard Portfolio Management, LLC
2.00M4.59%
Vanguard Capital Management, LLC
1.96M4.49%
State Street Corp
1.84M4.23%
Renaissance Technologies Corp
1.79M4.09%
Wellington Management Company LLP
1.38M3.16%
Geode Capital Management, LLC
1.23M2.83%
HHG PLC
866.93K1.99%
AQR Capital Management LLC
826.23K1.89%
NORGES BANK
694.75K1.59%
Genworth Financial Wealth Mgmt Inc
616.05K1.41%
Amvescap Plc.
608.37K1.39%
FMR Inc
528.35K1.21%
Dimensional Fund Advisors, Inc.
527.90K1.21%
Baillie Gifford & Co Limited.
467.21K1.07%

Top Fund Holders

iShares Core S&P Mid-Cap ETF
1.49M3.41%
Vanguard MStar Total Stk Mkt Idx Invest
1.35M3.09%
Vanguard Small Cap Index
976.67K2.24%
Vanguard Health Care Inv
756.63K1.73%

Stock Splits

Sep 23, 20092:1